IQV Stock Recent News

Growth in the Research and Development, and Technology and Analytics segments aids IQV's top line in the fourth quarter of 2024.

IQVIA Holdings Inc. (NYSE:IQV ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Kerri Joseph – Senior Vice President, Investor Relations and Treasury Ari Bousbib – Chairman and Chief Executive Officer Ron Bruehlman – Executive Vice President and Chief Financial Officer Conference Call Participants Shlomo Rosenbaum – Stifel Elizabeth Anderson – Evercore ISI Ann Hynes – Mizuho David Windley – Jefferies Charles Rhyee – TD Cowen Jack Meehan – Nephron Research Michael Ryskin – Bank of America Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2024 Earnings Conference Call.

On Thursday, IQVIA Holdings Inc IQV reported a fourth adjusted EPS of $3.12, up from $2.84, beating the consensus of $3.11.

Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

IQVIA Holdings (IQV) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $3.10 per share. This compares to earnings of $2.84 per share a year ago.

Contract research firm IQVIA Holdings beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare data and analytics services.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2024. "IQVIA delivered excellent fourth quarter performance, closing out a strong 2024," said Ari Bousbib, chairman and CEO of IQVIA. "R&DS revenue was on target and bookings exceeded o.

IQV's top line in the fourth quarter of 2024 is expected to have benefited from the rising use of GenAI to provide crucial insights.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World's Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on fou.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.